Equillium Inc. is a biotechnology company focused on developing innovative therapeutics to address unmet medical needs in severe autoimmune and inflammatory diseases
The company's research emphasizes harnessing the immune system to create targeted treatments for conditions such as autoimmune disorders and organ transplant rejection. With a commitment to advancing precision medicine, Equillium aims to improve patient outcomes through its pipeline of novel candidates, which are designed to modulate immune responses and provide more effective solutions for patients suffering from debilitating conditions.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Equillium's itolizumab showed improved longer-term outcomes in aGVHD despite missing primary endpoints. FDA feedback on potential Accelerated Approval is expected in May.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
